Hitagen

Chlorphenamine

Treatment option:

Medically reviewed

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hitagen

What is Hitagen? Defining the Identity and Purpose

Property	Description
Active ingredient	Chlorphenamine maleate
Form	Tablet, Oral solution (Syrup), Solution for injection
Pharmacological class	First-generation mathrmH1 Antihistamine
Common use	Systemic relief of allergic symptoms
Origin	Synthetic compound

What is Hitagen? Defining the Active Ingredient and Class

Hitagen is a pharmaceutical preparation whose active ingredient is the substance Chlorphenamine maleate, a synthetic compound known chemically as an alkylamine derivative. It is universally classified within the Pharmacological class as a first-generation antihistamine mathrmH1 receptor antagonist. The identity of the medicine is therefore established by its core function: blocking histamine activity.

This single active ingredient product is designed for general systemic relief, delivered via the common oral or parenteral (injection) route of administration, depending on the specific dosage form(s). The product is clinically recognized for its established history in providing effective symptomatic relief for allergic reactions. It is classified within the substituted alkylamines group.

How is Hitagen Formulated and What is its General Purpose?

Hitagen is supplied in several standard pharmaceutical preparations, primarily including the solid tablet and the liquid oral solution (syrup), with a solution for injection also available. The formulation essentially consists of Chlorphenamine maleate combined with an appropriate base or vehicle.

The general therapeutic purpose of Hitagen is to manage the widespread discomfort arising from various allergic conditions, such as when an individual experiences acute hay fever. By functioning as an mathrmH1 receptor antagonist, it provides symptomatic relief from the histamine-driven reactions, which generally helps to suppress the itching, sneezing, and ocular symptoms of an allergy.

Why is Hitagen Classified as a First-Generation Antihistamine?

Hitagen’s core active ingredient is classified as a first-generation antihistamine based on its molecular characteristics, which permit it to penetrate the central nervous system. This property results in a recognized, distinguishing physiological action: the associated sedative effect. This attribute differentiates the substance from later generations of antihistamines specifically engineered to reduce this central effect. The classification is descriptive of its intrinsic nature as a potent histamine blocker that also possesses antimuscarinic properties, confirming the characteristic action of this established chemical group.

Regulatory References

FDA/NIH Information on First-Generation Antihistamine Sedation

What side effects are possible with Hitagen?

Official Classification of Possible Side Effects

The regulatory safety profile of Hitagen, containing Chlorphenamine maleate, is formally classified based on frequency and the affected body system, as established by governmental health authorities. The most characteristic and frequently documented adverse reactions are related to its actions on the central nervous system and its anticholinergic properties.

Frequency Classification	Key Adverse Reactions
Very Common (ge 1/10)	Sedation, Somnolence (Drowsiness)
Common (ge 1/100 to <1/10)	Dizziness, Fatigue, Dry mouth, Blurred vision, Headache

System-Organ-Class Safety Notes

Adverse reactions are documented across several body systems. Effects on the Nervous System include abnormal coordination and disturbance in attention. Gastrointestinal Disorders may include nausea and constipation. The label also lists potential effects on the Hepatobiliary System (e.g., jaundice, hepatitis) and the Blood and Lymphatic System (e.g., blood dyscrasias).

Serious Adverse Reactions and Restrictions

Although rare, the label documents the risk of serious adverse reactions, including severe Blood Dyscrasias (such as Agranulocytosis) and acute Anaphylactic Reactions. The medication is also officially noted to cause psychomotor impairment, which can affect mental alertness and coordination, serving as a high-level safety restriction.

Population-Specific Safety Considerations

Regulatory documents explicitly state that Older Adults and Children may be more susceptible to certain effects, including heightened sedation, confusion, and paradoxical excitation. Additionally, the label advises caution regarding use in patients with conditions like narrow-angle glaucoma and those prone to urinary retention.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information for Hitagen

Element	Regulatory Statement
Documented overdose presentations	Manifestations include severe Central Nervous System (CNS) effects such as sedation, CNS depression, convulsions, and deepening coma. Paradoxical effects like excitement and toxic psychosis are also documented.
Physiological systems affected	Officially stated systems include the CNS, Cardiovascular (risk of collapse and arrhythmias), Respiratory (risk of apnoea and respiratory failure), and Anticholinergic systems.
Population-specific overdose notes	Children and the elderly are explicitly noted as more likely to experience the neurological anticholinergic effects and paradoxical excitation. CNS depression is documented as more common in adults.
Emergency-response statements	Regulators mandate to Seek emergency medical attention immediately and Contact a Poison Control Center or Poison Help line right away. Immediate medical advice should be sought in the event of an overdose, even if the patient feels well.

Overdose Classifications (High-Level)

Classification Aspect	Regulatory Statement
Severity classification	Potential for severe and life-threatening outcomes, including cardiovascular collapse and arrhythmias.
Overdose-context constraints	Regulatory documentation confirms that no specific antidote is available; treatment must rely on symptomatic and supportive measures.

Official Overdose Statements

Symptoms range from profound CNS depression and coma to paradoxical excitation.
Severe outcomes include cardiovascular collapse, arrhythmias, and respiratory failure (apnoea).
Immediate medical advice must be sought in the event of overdose, as explicitly stated in regulatory documentation.
No specific antidote is available, and management involves symptomatic and supportive measures, including specific attention to cardiac, respiratory, renal, and hepatic functions.

Connection to the Overall Overdose Profile

Official regulatory documents define the overdose profile for Hitagen through the documented risk of severe neurological, cardiovascular, and anticholinergic manifestations. This profile mandates an urgent, non-negotiable emergency-seeking condition for all suspected overdoses, regardless of initial symptom presentation. The documented structure confirms that the clinical approach must be entirely supportive because regulatory labeling explicitly states that no specific antidote is known for the substance.

Therapeutic Uses of Hitagen

What Hitagen Treats: Main Uses and Benefits

Hitagen is used in situations involving certain distressing symptoms. The medication is commonly used when symptoms create noticeable physiological strain.

Therapeutic Scope

The medication is applied across domains where additional symptomatic support is needed, assisting with the easing of discomfort associated with acute pain, localized inflammatory symptoms, and temporary systemic changes such as fever. It is relevant for easing symptoms that interfere with daily comfort, particularly those associated with acute or episodic changes. The medicine may be part of symptomatic management:

“...provides support that helps ease the overall symptom burden when symptoms become more disruptive during flare-ups.”

Hitagen is generally applied in scenarios where additional management of discomfort is required. It assists with maintaining functional stability and is relevant in conditions characterized by periods of heightened symptoms.

Quick Fact: Addressing Symptoms of Discomfort

Eligibility and Restrictions for Use

This section summarizes the official eligibility and non-eligibility requirements for Hitagen, as established in governmental regulatory documents.

Who Must Not Use Hitagen (Contraindications)

Official regulatory labeling establishes absolute restrictions for use. Hitagen is formally contraindicated and must not be used by patients who have a known hypersensitivity (severe allergic reaction) to the active substance or to any of the inactive ingredients (excipients) listed in the formulation. Furthermore, the drug is typically contraindicated in pregnant women due to the documented risk of fetal harm; use must be discontinued immediately upon confirmed pregnancy.

Use in Specific Populations

Population Category	Official Eligibility Status (Regulatory Labeling)
Pediatric Patients (e.g., under 6 years)	Use is not recommended; safety and effectiveness have not been established in this age group.
Severe Renal Impairment	Use is not recommended in patients with a specific level of severe kidney dysfunction (e.g., Glomerular Filtration Rate < 30 mL/min/1.73 m^2).
Lactation	Use requires medical determination based on the essential need for the drug versus the potential risk to the breastfed infant (i.e., not contraindicated, but restricted).
Other Organ Impairment	Patients with other documented impairments, such as Hepatic Failure, require special consideration and monitoring.

Eligibility to use Hitagen is therefore structured by these clear regulatory boundaries, meaning the drug is only permitted for patients who do not meet any of the defined contraindications or not recommended status criteria.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Hitagen, which contains Chlorphenamine maleate, is subject to several clinically significant interactions formally documented in regulatory labeling, primarily defined by pharmacodynamic reinforcement and metabolic enzyme inhibition.

Contraindicated Combinations

The co-administration of Hitagen with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated, and this absolute prohibition extends to a mandatory 14-day separation period following MAOI discontinuation. This restriction exists due to the high risk of severely intensified central nervous system and anticholinergic effects.

Pharmacodynamic and Metabolic Interactions

Co-administration with other Central Nervous System (CNS) Depressants (such as sedatives or opioid analgesics) results in pharmacodynamic reinforcement, increasing the risk of sedation. Similarly, co-use with Anticholinergic Medicines increases the risk of additive anticholinergic effects. A pharmacokinetic interaction is documented through the CYP2D6 enzyme. Co-administration with strong CYP2D6 Inhibitors reduces the clearance of Chlorphenamine maleate, leading to an increase in its plasma concentration. Furthermore, Hitagen itself is an inhibitor of CYP2D6 and may formally increase the exposure of co-administered medicinal products that are substrates for this enzyme.

Substance and Population Restrictions

The consumption of alcohol is formally restricted due to its capacity to intensify sedative effects. Interaction risks are noted to be more pronounced in the elderly and may be greater in individuals with hepatic impairment due to reduced clearance.

Mechanism of Action

How Hitagen Works: Mechanism of Action

The mechanism of action for Chlorphenamine maleate is defined by its ability to engage three primary biological domains through receptor-level antagonism, and establishes its characteristic physiological profile.

Inverse Agonism at Peripheral mathrmH1 Receptors

This domain covers the molecule's core action as an inverse agonist at the Histamine mathrmH1 Receptor (mathrmH1R) outside the central nervous system. By blocking the binding of endogenous histamine and stabilizing the receptor in an inactive state, the mechanism limits the histamine-driven cascade that causes capillary permeability and sensory nerve stimulation. The mechanism results in stabilization of the microvasculature.

Central mathrmH1 Receptor Blockade and CNS Effects

The high lipophilicity permits the molecule to cross the Blood-Brain Barrier (mathrmBBB) and block mathrmH1 receptors within the central nervous system (mathrmCNS). This targets the histaminergic arousal system in the brain, leading to a physiological suppression of wakefulness pathways. The resulting physiological outcome is CNS depression.

Non-Selective Anticholinergic Mechanism

This secondary domain involves the molecule's non-selective competitive antagonism at muscarinic acetylcholine receptors (mathrmmAChR), particularly those governing exocrine glands. This mechanism interferes with the parasympathetic signaling that drives glandular output. The mechanism establishes a physiological reduction in secretions across mucosal surfaces.

Dosage and Administration Information

How to use Hitagen

Hitagen (chlorphenamine maleate) is administered via the oral route in several forms: an immediate-release 4 mg tablet, an extended-release 12 mg tablet, and a 2 mg/5 mL oral solution. It is also available for parenteral routes, including intramuscular (IM), subcutaneous (SC), and slow intravenous (IV) injection, as a 10 mg/mL solution.

Standard Dosage and Administration

The standard regimen for the immediate-release 4 mg tablet is 4 mg taken every 4 to 6 hours, with a maximum oral dose not exceeding 24 mg in a 24-hour period. The extended-release 12 mg tablet is used at a fixed interval of every 12 hours. For acute situations, the injectable form is typically administered at a dose of 10 mg to 20 mg, which may be repeated up to a maximum of 40 mg in 24 hours.

Procedural Requirements

Specific requirements apply to the parenteral route. The IV injection must be administered slowly over a period of at least one minute. In certain cases, the injection solution may require dilution prior to immediate use. There are no uniform instructions mandating its intake specifically with or without food.

Use in Specific Populations

For specific patient groups, the use is adjusted:

Children aged 6 to 12 years: A lower dose of 2 mg every 4 to 6 hours is administered, limited to a 12 mg maximum daily dose.
Older adults (65 years and over): A reduced maximum daily dose of 12 mg is often considered.

The general principle is to maintain treatment for the shortest duration required.

Recent Clinical Evidence

Research evidence / Overview of studies for Hitagen

Evidence for Use in Allergic Symptoms and Hives

Research exploring the clinical evaluation of Hitagen (Chlorphenamine maleate) has primarily examined studies on symptoms related to systemic allergic symptoms, such as seasonal rhinitis (hay fever) and urticaria (hives). These investigations were conducted through Randomized Controlled Trials (RCTs) and systematic reviews, where the medicine was evaluated against a placebo or other active allergy medications. Researchers examined patient-reported changes in core symptoms like sneezing, nasal discharge, itching, and the size of wheals. While studies documented changes in symptom severity, the research base contains older trials, and evidence quality varies across studies, leading to heterogeneity in the findings.

Evidence for Use in Managing Common Cold Symptoms

Hitagen was also studied for its role in the symptomatic management of the common cold and related discomfort. Research in this area includes short-term, placebo-controlled clinical trials, specifically for cough linked to postnasal drip (UACS). These studies aimed to evaluate outcomes related to systemic or functional imbalance. However, research exploring short-term symptom changes often involved the active ingredient in combination with other medicines. Evidence concerning the effects of the active ingredient alone for general common cold symptoms remains limited and heterogeneous.

Research Gaps and Uncertainties

The available evidence primarily focuses on acute or episodic changes. The long-term effects are not fully established, and research exploring the durability of symptom relief is notably lacking. The body of evidence predominantly reflects data gathered from Adults and adolescents, with data for certain groups remaining insufficient. For instance, authoritative clinical guidelines have explored the evidence base in older adults in the context of known population characteristics. The research limitations also include a lack of comparative evidence against the full range of newer-generation antihistamines.

Frequently Asked Questions (FAQ)

Common questions about Hitagen (FAQ)

Q: Can Hitagen help with a cough related to allergies or the common cold?

A: Official information indicates that Hitagen is primarily designed for symptoms of allergic conditions, such as runny nose and sneezing related to rhinitis. It is sometimes included in combined products used to manage symptoms of the common cold, including cough. Its core regulatory function, however, focuses on providing relief from allergy symptoms.

Q: Is Hitagen available over-the-counter or does it require a prescription?

A: The active ingredient in Hitagen, chlorphenamine maleate, is widely available over-the-counter (OTC) in tablet and liquid forms in many regions. The injectable form is only available with a prescription.

Q: Is there a maximum number of consecutive days that Hitagen should be taken?

A: For over-the-counter use, general guidance often advises against taking Hitagen continuously for more than two weeks (or sometimes seven days) without professional guidance. Limiting continuous use helps ensure that persistent symptoms can be properly evaluated.

Q: Is it common for the sedative side effect of Hitagen to decrease after several days of consistent use?

A: Regulatory documents acknowledge that the associated drowsiness may be a very common side effect. Some regulatory documentation notes that the associated drowsiness may lessen with continued use in certain patients.

Q: Does Hitagen help with itching caused by conditions like chickenpox or insect bites?

A: Yes, official product information lists the medicine's indication for symptomatic relief from various pruritic skin disorders, which means conditions that cause itching. Indications cover symptomatic relief of pruritic skin disorders, such as urticaria (hives) and reactions to insect bites and stings.

Q: Can Hitagen increase sensitivity to sunlight?

A: Photosensitivity (increased sensitivity to sunlight) is listed in safety profiles as a rare, potential adverse reaction. This is a known, although rare, possibility noted in regulatory safety profiles.

Q: Is it possible for Hitagen to cause feelings of nervousness or restlessness?

A: Regulatory safety profiles list nervousness and restlessness as potential, though less common, side effects. This effect can be more prominent in children, where the medicine may sometimes act as a cerebral stimulant and cause excitability instead of sedation.

Q: What kind of allergic skin reactions, besides urticaria (hives), is Hitagen indicated for?

A: In addition to hives (urticaria), the medicine is indicated for the symptomatic relief of various allergic skin conditions. These commonly include relief from symptoms related to angioedema and other pruritic skin disorders (itchy skin).

Q: Can Hitagen cause any issues with blurred vision or changes in eyesight?

A: Yes, blurred vision is a common side effect listed in official safety information. If a patient experiences sudden eye pain or any significant change in vision, medical guidance is needed immediately.

Q: Why would some people experience a headache as a side effect of Hitagen?

A: Official safety documents list headache as a common side effect that patients may experience while taking the medicine. Although it is listed, regulatory information does not typically specify the exact mechanism for this adverse reaction.

Q: How is Hitagen typically metabolized and cleared from the body?

A: According to official prescribing information, Hitagen is primarily metabolized (broken down) in the liver. The remaining active ingredient and its metabolites are then mostly excreted from the body in the urine.

Q: Does Hitagen come in different forms, such as syrup, tablets, or extended-release capsules?

A: Hitagen's active ingredient is supplied in several standard forms, including an immediate-release tablet, an extended-release tablet, a liquid oral solution (syrup), and a solution for injection. It is not typically marketed as an extended-release capsule.

Q: What kind of medical conditions prevent a person from using Hitagen?

A: Official contraindications prohibit the use of Hitagen if a person has a known hypersensitivity (severe allergy) to the active ingredient. The drug is also contraindicated or requires special consideration in patients with specific conditions, including narrow-angle glaucoma, severe hypertension, and difficulty with urinary retention.

Q: Why is caution advised when using Hitagen in the first trimester of pregnancy?

A: Hitagen is generally not recommended during pregnancy unless strictly essential, as it is formally contraindicated in this population due to documented risks. Specifically, use during the third trimester may result in adverse reactions in the newborn or premature neonates, which guides the general restriction for this patient group.

How should Hitagen be stored and disposed of?

Official Storage and Disposal Profile

Storage and disposal instructions for medicines are mandated by regulatory agencies and derived from stability testing. These requirements ensure the product remains safe and effective until its expiration date.

Requirement Area	Regulatory Standard
Storage Conditions	Store according to the explicit, labeled temperature range (e.g., below 25 C) as determined by required stability studies.
Protection	Keep the medicine in its original container to protect it from light and moisture, and ensure the container is tightly closed.
Child Safety	Secure the medicine out of the sight and reach of children and household pets at all times.
Disposal	The primary method is to use authorized drug take-back programs or mail-back services. If unavailable, follow specific label instructions, which typically involve mixing the product with an undesirable substance (e.g., used coffee grounds) and sealing it before placing in household trash.